CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice

Babaev, 2000, Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice, J Biol Chem, 275, 26293, 10.1074/jbc.M002423200 Benzaquen, 1994, Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells, J Exp Med, 179, 985, 10.1084/jem.179.3.985 Bhakdi, 1999, Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation, Arterioscler Thromb Vasc Biol, 19, 2348, 10.1161/01.ATV.19.10.2348 Bhatia, 2007, Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice, Am J Pathol, 170, 416, 10.2353/ajpath.2007.060406 Buono, 2002, Influence of C3 deficiency on atherosclerosis, Circulation, 105, 3025, 10.1161/01.CIR.0000019584.04929.83 Halperin, 1993, Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells, J Clin Invest, 91, 1974, 10.1172/JCI116418 Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, 352, 1685, 10.1056/NEJMra043430 Kim, 2008, Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg, Blood, 112, 1109, 10.1182/blood-2008-01-134304 Kim, 2006, Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack, J Immunol, 177, 5558, 10.4049/jimmunol.177.8.5558 Li, 2004, C-reactive protein upregulates complement-inhibitory factors in endothelial cells, Circulation, 109, 833, 10.1161/01.CIR.0000117087.27524.0E Liu, 2005, The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo, J Exp Med, 201, 567, 10.1084/jem.20040863 Longhi, 2006, Holding T cells in check--a new role for complement regulators?, Trends Immunol, 27, 102, 10.1016/j.it.2005.12.008 Longhi, 2005, Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner, J Immunol, 175, 7098, 10.4049/jimmunol.175.11.7098 Lublin, 1989, Decay-accelerating factor: biochemistry, molecular biology, and function, Annu Rev Immunol, 7, 35, 10.1146/annurev.iy.07.040189.000343 Mackness, 1997, Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis, Arterioscler Thromb Vasc Biol, 17, 1233, 10.1161/01.ATV.17.7.1233 Mason, 2002, Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury, Circ Res, 91, 696, 10.1161/01.RES.0000038151.57577.19 Miwa, 2002, Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice, Am J Pathol, 161, 1077, 10.1016/S0002-9440(10)64268-X Miwa, 2002, Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack, Blood, 99, 3707, 10.1182/blood.V99.10.3707 Molina, 2002, Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor., Blood, 100, 4544, 10.1182/blood-2002-06-1875 Mollnes, 2002, Complement in inflammatory tissue damage and disease, Trends Immunol, 23, 61, 10.1016/S1471-4906(01)02129-9 Morgan, 1993, Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase, Eur J Immunol, 23, 2841, 10.1002/eji.1830231118 Murray, 1998, Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement, J Biol Chem, 273, 25279, 10.1074/jbc.273.39.25279 Nicholson-Weller, 1982, Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system, J Immunol, 129, 184, 10.4049/jimmunol.129.1.184 Nicoletti, 1998, Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice, J Clin Invest, 102, 910, 10.1172/JCI119892 Niculescu, 1999, Complement activation and atherosclerosis, Mol Immunol, 36, 949, 10.1016/S0161-5890(99)00117-0 Niculescu, 2004, The role of complement activation in atherosclerosis, Immunol Res, 30, 73, 10.1385/IR:30:1:073 Niculescu, 1987, Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis, Atherosclerosis, 65, 1, 10.1016/0021-9150(87)90002-5 Niculescu, 1990, Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall, Immunol Lett, 26, 17, 10.1016/0165-2478(90)90170-U Okada, 1989, A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement, Int Immunol, 1, 205, 10.1093/intimm/1.2.205 Oksjoki, 2003, Role of complement activation in atherosclerosis, Curr Opin Lipidol, 14, 477, 10.1097/00041433-200310000-00008 Patel, 2001, ApoE(−/−) mice develop atherosclerosis in the absence of complement component C5, Biochem Biophys Res Commun, 286, 164, 10.1006/bbrc.2001.5276 Patrono, 1997, Isoprostanes: potential markers of oxidant stress in atherothrombotic disease, Arterioscler Thromb Vasc Biol, 17, 2309, 10.1161/01.ATV.17.11.2309 Persson, 2004, Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E −/− low-density lipoprotein receptor −/− mice, Arterioscler Thromb Vasc Biol, 24, 1062, 10.1161/01.ATV.0000127302.24266.40 Pratico, 1997, Localization of distinct F2-isoprostanes in human atherosclerotic lesions, J Clin Invest, 100, 2028, 10.1172/JCI119735 Rokach, 1997, Nomenclature of isoprostanes: a proposal, Prostaglandins, 54, 853, 10.1016/S0090-6980(97)00184-6 Rollins, 1990, The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9, J Immunol, 144, 3478, 10.4049/jimmunol.144.9.3478 Rudic, 2005, COX-2-derived prostacyclin modulates vascular remodeling, Circ Res, 96, 1240, 10.1161/01.RES.0000170888.11669.28 Schmiedt, 1998, Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits, Arterioscler Thromb Vasc Biol, 18, 1790, 10.1161/01.ATV.18.11.1790 Seifert, 1989, Complement receptors and regulatory proteins in human atherosclerotic lesions, Arteriosclerosis, 9, 802, 10.1161/01.ATV.9.6.802 Seifert, 1989, Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions, J Clin Invest, 84, 597, 10.1172/JCI114204 Sogabe, 2001, Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis, J Immunol, 167, 2791, 10.4049/jimmunol.167.5.2791 Song, 2000, Complement and innate immunity, Immunopharmacology, 49, 187, 10.1016/S0162-3109(00)80303-3 Song, 2007, Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method, Methods Enzymol, 433, 51, 10.1016/S0076-6879(07)33003-6 Sun, 1999, Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting, Proc Natl Acad Sci U S A, 96, 628, 10.1073/pnas.96.2.628 Tangirala, 1995, Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice, J Lipid Res, 36, 2320, 10.1016/S0022-2275(20)39713-3 Vlaicu, 1985, Immunoglobulins and complement components in human aortic atherosclerotic intima, Atherosclerosis, 55, 35, 10.1016/0021-9150(85)90164-9 Vlaicu, 1985, Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall, Med Interne, 23, 29 Walport, 2001, Complement. First of two parts, N Engl J Med, 344, 1058, 10.1056/NEJM200104053441406 Walport, 2001, Complement. Second of two parts, N Engl J Med, 344, 1140, 10.1056/NEJM200104123441506 Wang, 2008, Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation, Circulation, 117, 1302, 10.1161/CIRCULATIONAHA.107.731398 Yun, 2008, Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59, Arterioscler Thromb Vasc Biol, 28, 1714, 10.1161/ATVBAHA.108.169912